基于18F-FDG PET/CT反应在局部晚期食管鳞癌根治性放化疗中进行剂量递增:一项III期、开放标签、随机对照试验(ESO-Shanghai 12)
ESO-Shanghai 12是一项前瞻性多中心随机III期试验,将局部晚期食管鳞癌患者按PET/CT反应随机分配至61.2 Gy或50.4 Gy放疗剂量,两组均接受紫杉醇/顺铂方案同步放化疗2周期后巩固化疗2周期。主要终点为PET/CT无反应者(SUVmax > 4.0)的总生存期和总人群的总生存期。
要点
- 标准根治性放化疗剂量为50-50.4 Gy,18F-FDG PET/CT有潜力为对放化疗无反应的食管癌患者定制治疗。
- 试验将患者随机分配至61.2 Gy或50.4 Gy放疗剂量,同步紫杉醇/顺铂方案化疗2周期后巩固化疗2周期。
- 主要终点为PET/CT无反应者(SUVmax > 4.0)的总生存期和总人群的总生存期。
核心结论
- 该试验旨在研究基于18F-FDG PET/CT反应的剂量递增(61.2 Gy vs 50.4 Gy)在局部晚期食管鳞癌根治性放化疗中的价值,目前正在招募患者。
研究设计与样本
- ESO-Shanghai 12是一项前瞻性多中心随机III期研究,患者按PET/CT反应随机分配至61.2 Gy或50.4 Gy放疗剂量组。
- 入组标准为组织学确诊的ESCC,分期为T1N1-3M0、T2-4NxM0、TxNxM1(仅锁骨上淋巴结转移)(AJCC癌症分期手册第8版),且既往未接受过针对食管癌的化疗、放疗或手术。
- 患者按标准化摄取值体积、大体肿瘤体积和肿瘤位置进行分层。
- 当PET/CT无反应者达到132例且总人群达到646例进行随机化时,可结束入组。
主要发现
- 两组均接受紫杉醇/顺铂方案同步放化疗2周期,随后巩固化疗2周期。
- 主要终点包括PET/CT无反应者(SUVmax > 4.0)的总生存期和总人群的总生存期。
关键数值与推荐
- PET/CT无反应定义为SUVmax > 4.0。
- 放疗剂量:试验组61.2 Gy,对照组50.4 Gy。
- 同步化疗方案为紫杉醇/顺铂,2周期,随后巩固化疗2周期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Definitive chemoradiotherapy has established the standard non-surgical treatment for locally advanced esophageal cancer. The standard dose of 50-50.4 Gy has been established decades ago and been confirmed in modern trials. The theorical advantage of better local control and technical advances for less toxicity have encouraged clinicians for dose escalation investigation. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) have the potential to tailor therapy for esophageal patients not showing response to CRT and pioneers the PET-based dose escalation. METHODS AND ANALYSIS: The ESO-Shanghai 12 trial is a prospective multicenter randomized phase 3 study in which patients are randomized to either 61.2 Gy or 50.4 Gy of radiation dose by PET response. Both groups undergo concurrent chemoradiotherapy with paclitaxel/cisplatin regimen for 2 cycles followed by consolidation chemotherapy for 2 cycles. Patients with histologically confirmed ESCC [T1N1-3M0, T2-4NxM0, TxNxM1 (Supraclavicular lymph node metastasis only), (AJCC Cancer Staging Manual, 8th Edition)] and without any prior treatment of chemotherapy, radiotherapy or surgery against esophageal cancer will be eligible. The primary endpoints included overall survival in PET/CT non-responders (SUVmax > 4.0) and overall survival in total population. Patients will be stratified by standardized uptake volume, gross tumor volume and tumor location. The enrollment could be ended, when the number of PET/CT non-responder reached 132 and the total population reached 646 for randomization. ETHICS AND DISSEMINATION: This trial has been approved by the Fudan University Shanghai Cancer Center Institutional Review Board. Trial results will be disseminated via peer reviewed scientific journals and conference presentations. Trial registration The trial was initiated in 2018 and is currently recruiting patients. Trial registration number NCT03790553.
引用
- Zhu H, Liu Q, Xu H, et al. Dose escalation based on 18F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12). Radiat Oncol. 2022. PMID: 35906623. doi:10.1186/s13014-022-02099-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。